Evotec (EVO)

• Market cap: $1.45B
• 1 day: -1.64%
• 5 days: 1.45%
• 1 month: 25.75%
• 3 months: -6.46%
• 6 months: 6.06%
• Year to date: -1.64%
• 1 year: -19.08%
• 5 years: -80.91%
• 10 years: -80.91%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Employees: 4,827

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

25% more capital invested

Capital invested by funds: $29.6M [Q3] → $36.9M (+$7.31M) [Q4]

8% more funds holding

Funds holding: 24 [Q3] → 26 (+2) [Q4]

0.5% more ownership

Funds ownership: 4.5% [Q3] → 5.0% (+0.5%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7